All News

Rachel Rubin, MD, discusses advancements in sexual health education and guidelines at the AUA meeting.

In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.

"The biggest message from this study is that 60% can expect resolution of UUI, simply by fixing the prolapse and placing a sling, which is not normally indicated for UUI," according to Christina M. Mezes, DO, and Catherine A. Matthews, MD.

A recap of the FDA submissions and regulatory decisions in urology from March 2025.

The test can deliver diagnostic results for chlamydia, gonorrhea, and trichomoniasis.

"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, PharmD, MS, MBA, CPEL.

The approval is supported by data from the phase 3 EAGLE-2 and EAGLE-3 trials.

"The findings from this study will help us understand sunobinop’s potential as a possible new treatment option for this chronic disorder,” said Craig Landau, MD.

Age, race, and hormonal contraceptive use did not significantly impact the efficacy of sildenafil cream, 3.6%, in female sexual arousal disorder.

“These findings support the safety of vaginal estrogen for treatment of local menopause symptoms, even in high-risk women,” says Gabriella M. Rustia, MD.

Data showed that vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers may provide benefit in the management of symptoms related to GSM.

The company expects the device to become available for US patients with pelvic organ prolapse in September 2024.

There were no differences in the number of treatment-related TEAEs in patients who received sildenafil cream vs patients who received placebo.

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

Developed by the AUGS Scientific Committee and Research Agenda Writing Group

The FDA approval is supported by data from the phase 3 ALLIUM trial, which demonstrated the non-inferiority and superiority of cefepime/enmetazobactam vs piperacillin/tazobactam.

The aim of this document is to present a framework by which AUGS and its members can address the development of new technology and techniques, particularly in the surgical arena.

The FDA has issued a complete response letter regarding a new drug application for cefepime-taniborbactam for the treatment of patients with complicated urinary tract infection.

The position statement is meant to iterate AUGS' support for gender inclusion of both patients and health care providers.

Cefepime-taniborbactam is currently under review by the FDA for cUTI, including acute pyelonephritis, based on data from the CERTAIN-1 trial.

The purpose of this clinical consensus statement is to identify areas of expert consensus and nonconsensus regarding pessary fitting, follow-up, and management of pessary complications to improve the safety and quality of care where evidence is currently limited.

Iterum plans to resubmit a New Drug Application for oral sulopenem for the treatment of patients with uUTi in Q2 of 2024.

The goals of the American Urogynecologic Society (AUGS) program are to support novel clinical, translational, and bench research pilot projects and enable early career investigators to obtain future independent funding for research.

There are several new CPT codes for 2024, including Category III codes for tibial nerve stimulation and other changes to codes in the treatment of urinary incontinence.

NRX-101 is a fixed-dose combination of the broad-spectrum antibiotic D-cycloserine and lurasidone.

Amy Luckenbaugh, MD, is an assistant professor of Urology at Vanderbilt University Medical Center.

The IND clearance will initiate a phase 2 registrational study to investigate the safety and efficacy of NRX-101 in patients with complicated UTIs.

Hadley Wood, MD, shares her vision as the new editor-in-chief of Urology.

"I'm thrilled to continue my partnership with SMPA to educate and empower others to address their OAB," says Holly Robinson Peete.

“This study confirms what many women who’ve struggled with persistent UTIs already know, which is that the current methods of diagnosing and treating these infections are inadequate," says Jennifer Rohn, PhD.